MarketPlays: Novo Nordisk Stock (NVO) Price, Earnings & Analysis

Company Overview

Name

Novo Nordisk

52W High

$61.21

52W Low

$34.20

Market Cap

$170.6B

Dividend Yield

6.173%

Price/earnings

3.6235

P/E

3.6235

Dividends

Dividends Predicted

Feb 23, 2027

$0.58 per share

Sentiment

Score

Bullish

Low

Neutral

High

100

Trade Volume

Score

Neutral

Low

Neutral

High

100

Income Statement

Total Revenue

$48.6B

Operating Revenue

$48.6B

Total Gross Profit

$39.3B

Total Operating Income

$20.1B

Net Income

$16.1B

EV to EBITDA

$8.16

EV to Revenue

$3.95

Price to Book value

$5.65

Price to Earnings

$10.70

Additional Data

Selling, General & Admin Expense

$11B

Research & Development Expense

$8.2B

Other Operating Expenses / (Income)

$47.1M

Total Operating Expenses

$-19.3B

Interest Expense

$-1.1B

Interest & Investment Income

$1.5B

Earnings History

Estimated EPS

Reported EPS

N/A

Company Overview

Name

Novo Nordisk

52W High

$61.21

52W Low

$34.20

Market Cap

$170.6B

Dividend Yield

6.173%

Price/earnings

3.6235

P/E

3.6235

Dividends

Dividends Predicted

Feb 23, 2027

$0.58 per share

Sentiment

Score

Bullish

Low

Neutral

High

100

Trade Volume

Score

Neutral

Low

Neutral

High

100

Income Statement

Total Revenue

$48.6B

Operating Revenue

$48.6B

Total Gross Profit

$39.3B

Total Operating Income

$20.1B

Net Income

$16.1B

EV to EBITDA

$8.16

EV to Revenue

$3.95

Price to Book value

$5.65

Price to Earnings

$10.70

Additional Data

Selling, General & Admin Expense

$11B

Research & Development Expense

$8.2B

Other Operating Expenses / (Income)

$47.1M

Total Operating Expenses

$-19.3B

Interest Expense

$-1.1B

Interest & Investment Income

$1.5B

Earnings History

Estimated EPS

Reported EPS

N/A

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

Lars F. Jørgensen

Location

N/A, Denmark

Exchange

NYSE

Website

https://novonordisk.com

Summary

Novo Nordisk A/S engages in the research, development, manufacture, and marketing of pharmaceutical products.

Company Info

CEO

Lars F. Jørgensen

Location

N/A, Denmark

Exchange

NYSE

Website

https://novonordisk.com

Summary

Novo Nordisk A/S engages in the research, development, manufacture, and marketing of pharmaceutical products.

4 min read

Quick Summary

Novo Nordisk A/S is a leading healthcare company engaged in the research, development, manufacture, and marketing of pharmaceutical products, predominantly specializing in the treatment of diabetes and obesity. The company operates through two main segments: Diabetes and Obesity Care, which focuses on products like insulins, GLP-1 and related delivery systems, oral antidiabetic medications, and treatments for obesity and other chronic diseases. It also has a Biopharmaceuticals segment dedicated to haemophilia, growth disorders, and hormone replacement therapy. Founded in 1923 and headquartered in Bagsvaerd, Denmark, Novo Nordisk serves a global market and aims to expand its reach through strategic investments and innovations. The company's products are geared towards improving the quality of life for patients worldwide, with a strong commitment to research and development in the healthcare sector.

Strengths

•

Novo Nordisk excels in diabetes and obesity care, supported by a robust portfolio of insulin and GLP-1 products, which have reinforced its position as a market leader.

•

The company benefits from extensive research and development capabilities, consistently bringing innovative therapies to market.

•

Strong brand recognition and a century-long heritage in the pharmaceutical industry contribute to patient trust and global reach.

•

Moreover, recent successful expansions and strategic investments in production facilities bolster its competitive edge.

•

Additionally, Novo's ability to effect significant price reductions while maintaining high-quality standards reflects strategic acumen and operational strength.

Key Risks

•

Novo Nordisk faces multiple risks, including rising competition in the diabetes and obesity segments, where companies like Eli Lilly pose substantial threats.

•

Market volatility and regulatory hurdles can disrupt strategic plans, while drug price pressures from competitors and generics may impact profit margins.

•

Additionally, geographical expansion presents risks related to political and economic instability, potentially affecting operations and cost structures.

•

The inherent risks associated with clinical trials, as demonstrated by the CagriSema results, also pose threats to investor confidence and future product launches.

What to Watch

During the most recent quarter, Novo Nordisk made significant strides by launching the online pharmacy NovoCare, offering its obesity drug Wegovy at a reduced price for cash-paying patients.

This strategic pricing move aimed at enhancing accessibility is expected to boost sales figures.

Novo also initiated investments worth $1.09 billion for expanding its Brazilian plant, aligning with its global expansion strategy for enhanced GLP-1 drug production.

However, the quarter was marked by a setback with Novo's weight-loss drug, CagriSema, underperforming in trials, leading to a notable stock decline.

Despite these challenges, the company remained focused on strengthening its supply chain and maintaining its market leadership.

Price Drivers

•

Novo Nordisk's stock price is significantly influenced by its product performance, particularly the sales and market reception of its diabetes and obesity treatments.

•

Macroeconomic factors, including product shortages and regulatory approvals, also play crucial roles.

•

Competition from major pharmaceutical companies, like Eli Lilly, can sway investor sentiment and drive stock volatility.

•

Furthermore, innovations and strategic expansions, such as the development of new production facilities, impact the company’s market valuation.

•

Overall, the prospects of robust growth in the diabetes and obesity markets are key drivers of Novo's valuation metrics.

Recent News

•

Recent news highlights Novo Nordisk's strategic investment of $1.09 billion in its Brazilian facility to boost GLP-1 drug production, cementing its global strategic footprint.

•

They launched the NovoCare online pharmacy, offering Wegovy at a reduced cash price, which resulted in a temporary stock price rise.

•

However, traction was marred by the underperformance of the weight-loss drug CagriSema, leading to a significant stock decline.

•

Despite this, Novo remains committed to addressing trial shortcomings by planning new tests to improve drug outcomes.

•

Analysts continue to view Novo favorably but suggest rising competition from AI sectors poses intriguing comparative investment prospects.

Market Trends

•

The healthcare market is witnessing a transformative phase driven by rapidly growing demands for diabetes and obesity management solutions amid rising global health concerns.

•

There is an increasing focus on innovation and technology integration, with AI-driven healthcare startups garnering investor attention, potentially overshadowing traditional pharmaceuticals like Novo Nordisk in terms of perceived dynamism.

•

Cost pressures and the growing trend towards personalized medicine are pushing companies towards establishing competitive pricing strategies.

•

Regulatory changes continue to shape market accessibility and the operational landscapes for drug approvals and launches.

•

Furthermore, digital health's emergence underscores the importance of aligned pharmaceutical and tech efforts in patient management.

AI-generated summary for educational purposes only. Not investment advice. Always do your own research before investing.